Objectives: To characterize the gut hormone profile and determine the effect of satiety gut hormone blockade on food intake in disease-free postesophagectomy patients. Background: Improved oncologic outcomes for esophageal cancer have resulted in increased survivorship and a focus on health-related quality of life. Anorexia and early satiety are common, but putative causative factors, in particular the gut-brain hormonal axis, have not been systematically studied. Methods: In a double-blind, placebo-controlled, randomized crossover study, disease-free patients at least 1 year postresection and gastric conduit reconstruction received either 1 mL 0.9% saline or 1 mL (100 mg) octreotide acetate subcutaneously followed by a standardized ad libitum meal on each of two assessments. Fasting and postprandial plasma glucagon-like peptide 1 (GLP-1), peptide YY (PYY), and ghrelin immunoreactivity were measured. Gut hormone responses and calorie intake postsaline versus octreotide were compared between experimental and control groups. Results: Eighteen subjects [esophagectomy (ES), n ¼ 10, 2.4 AE 0.75 years postresection; and unoperated control subjects, n ¼ 8] were studied. ES demonstrated significant weight loss at 3, 6, 12, and 24 months postoperatively (all P < 0.05). Ghrelin levels were similar (P ¼ 0.58) for both groups, but postprandial GLP-1 and PYY responses were significantly (P < 0.001) greater among ES as compared with controls. After octreotide, ad libitum calorie intake increased among ES (1.5 AE 0.2 fold-change, P ¼ 0.02) but not controls (1.1 AE 0.1 fold-change, P ¼ 0.30). Conclusions: ES demonstrated an exaggerated postprandial satiety gut hormone response that was attenuated by octreotide, thus identifying a potential therapeutic target to modulate in the ES patient with early satiety.
M
any factors, including advances in perioperative care, improved staging, earlier diagnosis, and increased centralization of cancer surgery have resulted in reduced operative mortality and improved oncologic outcomes in esophageal cancer (EC) patients treated with curative intent. 1 The recent CROSS randomized controlled trial established a benchmark three-year survival of 58% for locally advanced cancer after multimodal therapy. [1] [2] [3] With improved early and long-term survivorship, there is an increasing focus on qualitative improvements, including enhanced recovery, and on understanding and improving the myriad issues impacting on postoperative health related quality of life. Commonly reported, but incompletely understood, are persistent weight loss, reduced hunger, and early satiety. [4] [5] [6] [7] [8] [9] [10] [11] [12] Irrespective of etiology, malnutrition is particularly prevalent and may become chronic. [5] [6] [7] Approximately, one third of recurrence-free patients have more than 15% body weight loss at 3 years after esophagectomy. 7 Altered appetite is common after major gastrointestinal surgery 8, 9, 11, 12 and early postoperative reductions in the orexigenic hormone ghrelin may play a role in the pathogenesis of diminished hunger after esophagectomy. [13] [14] [15] [16] [17] [18] However, the role of ghrelin deficiency as a driver of long-term reduced weight after esophagectomy is controversial. 16,18 -20 Early satiety persists in approximately 90% of patients 1 year after surgery. 8 Reduced meal size may impair the patient's participation in the social aspects of eating, whereas altered eating regimens targeting body weight maintenance may impact functional status 21 and reinforce a persistent illness-identity even among those attaining long-term remission, hence early satiety has major implications for overall quality of life. 4, 8, 11, 12, 21 A new understanding of the gut-brain interaction underpinning the control of hunger and satiety has recently emerged, largely through clinical and experimental models in bariatric surgery. 22, 23 Meal termination is regulated by both neural signals and humoral mediators which are secreted from the gastrointestinal tract in response to various phases of ingestion (Fig. 1) . [22] [23] [24] The satiety gut hormones including glucagon-like peptide 1 (GLP-1) and peptide YY (PYY) are secreted from the enteroendocrine L-cells of the small and large intestine in response to luminal nutrients and reduce food intake by modulating appetitestimulating neurons in the hypothalamic arcuate nucleus. 22, 25 Exaggerated postprandial gut hormone responses are thought to contribute to increased satiety and reduced food intake after Roux-en-Y gastric bypass (RYGB) and vertical sleeve gastrectomy (VSG) for morbid obesity. 23, 26, 27 D-cell somatostatin release is stimulated by GLP-1 and provides a negative feedback signal to the L-cell, [28] [29] [30] a function retained by the somatostatin analog octreotide. 27 A solitary previous report demonstrated elevated postprandial GLP-1 concentrations in a series of ten patients postesophagectomy. 31 In the current study, we explored the pattern of key hormones including GLP-1, PYY, and ghrelin in disease-free survivors after esophagectomy. We investigated within a randomized trial the hypothesis that the potent inhibitory effect of octreotide on L-cell secretion could modulate exaggerated postprandial enteroendocrine responses and consequently early meal termination postesophagectomy.
From the

METHODS
Study Participants and Data Collection
The Esophageal and Gastric Center at St. James's Hospital, Dublin, is a high volume National Center, and detailed clinical, demographic, staging, treatment, pathologic, and follow-up information is prospectively maintained for all patients with a diagnosis of esophageal cancer. For the esophagectomy (ES) group, weight-stable patients without evidence of disease recurrence on surveillance computed tomography at least 1 year after resection were considered for inclusion. Only those with gastric conduit reconstruction and pyloroplasty were eligible, whereas a major surgical complication (Clavien-Dindo grade IIIb or greater), 32 or symptomatic anastomotic stricture resulted in exclusion. Consecutively diagnosed, eligible patients were identified and invited to participate. Age, weight, and sex-matched weight-stable control subjects with nondysplastic Barrett's esophagus were identified from the National Barrett's Esophagus Registry, and represent the control group. For both groups, patients with previous gastrointestinal surgery, major systemic, or neuropsychiatric disease were considered ineligible.
The institutional Research Ethics Committee approved the study (REC 2011-27-01), which was conducted in accordance with the principles of the Declaration of Helsinki with all patients providing written informed consent.
Treatment
Neoadjuvant Therapy
For patients with predicted locally advanced disease during this period, the preoperative chemoradiotherapy (CRT) regimen comprised Cisplatin and 5-Fluorouracil and external beam radiotherapy consisting of 40 Gy administered in 15 fractions, as previously described. 33 Surgery was scheduled 6 weeks after completion of CRT.
Surgery
All patients with predicted locally advanced type I/II adenocarcinoma of the esophagogastric junction (AEG) underwent abdominal-thoracic en bloc esophagectomy with thoracic or cervical anastomosis. Those with early malignant lesions underwent either abdominal-thoracic en bloc esophagectomy with thoracic anastomosis or transhiatal resection, as previously described. 2, 34 Reconstruction using a posterior mediastinal gastric conduit approximately 5 cm in width with hand-sewn anastomosis and pyloroplasty was performed as routine.
Nutritional Assessment and Support
As per institutional protocol, all patients were reviewed in the multidisciplinary clinic and received detailed dietetic consultation and assessment before esophagectomy. 35 Height, premorbid and serial body weight (BW) measurements were obtained as previously described. 35 A 10 Fr needle catheter jejunostomy (NCJ) was routinely placed at surgery, and NCJ feeding was commenced on the first postoperative day. 35, 36 Patients began oral intake on postoperative day four or five. NCJ feeding was continued until at least day 21 postoperatively when ongoing requirements for supplemental enteral feeding were assessed. 35 Patients' nutritional status was then reviewed at 3, 6, 12, and 18 months postoperatively, or more frequently as clinically indicated. Patients were routinely maintained on proton pump inhibitors postoperatively.
Study Design and Protocol
This was a randomized, double-blind, placebo controlled, and crossover study (Fig. 2 ) of the effect of single dose octreotide on ad libitum food intake (primary outcome measure) in disease-free postesophagectomy subjects, compared with unoperated matched controls. Power calculations based on previously published data 27 determined that six subjects per group should complete the study protocol to detect a 50% AE 30% increase in ad libitum food intake with 90% power at P < 0.05. Ten subjects were recruited per group to mitigate potential midprotocol drop-out. Computer-generated randomization and dispensing was performed by a single, unblinded investigator who had no interaction with study participants [RMcH] .
Each participant was admitted to the St. James's Hospital, Wellcome Trust-Health Research Board Clinical Research Facility at 09:00 after a 12-hour fast on two occasions at least 7 days apart.
A single blinded investigator [JAE] assessed all patients. Subjects received 1 mL 0.9% saline or 100 mg (1 mL) octreotide acetate by subcutaneous (SC) injection on each of two study visits. An ad libitum meal was provided 80 minutes after SC injection. To control for the rate of eating, 50 mL (108 kcal) of a homogenous semiliquid standard meal (4.2% protein, 17.0% fat, 20.2% carbohydrate) was provided every 5 minutes until the subjects indicated that they were comfortably full. Plasma samples were obtained from a peripheral intravenous cannula immediately before and at 75, 100, 130, and 160 minutes after SC injection. Visual analog scales (VAS) ranging from 0 to 100 mm were used to measure hunger, fullness, and nausea immediately before and at 40, 55, and 80 minutes after SC injection, and at 5, 10, 20, 40, and 60 minutes after completion of the ad libitum meal. 
Plasma Analysis
Plasma total GLP-1, PYY, and ghrelin levels were measured by enzyme-linked immunosorbent assay [Multispecies GLP-1 Total ELISA, Human PYY (Total) ELISA and Human Ghrelin (Total) ELISA, Merck Millipore, Darmstadt, Germany] validated to detect in the picomolar range with intraassay and interassay variability of <6% and <16%, respectively. Plasma glucose levels were determined using an automated analyzer (Cobas8000, Roche Diagnostics, Hoffmann-La Roche, Basel, Switzerland).
Statistical Analysis
Data were analyzed using GraphPad Prism (version 6.0) for Windows, GraphPad software (San Diego, CA). Data are presented as mean AE standard error unless otherwise specified. Univariate within-group comparisons were analyzed using paired Student's t or Wilcoxon signed rank test, as appropriate. Univariate betweengroup comparisons were performed using the Student's t or MannWhitney U tests for continuous variables or x 2 or Fischer exact test for categorical variables. Correlative analysis was performed using the Spearman Rho rank test. One way repeated measures analysis of variance (ANOVA) with post hoc Dunnett's test was used to analyze differences in BW from baseline. All statistical analyses were twotailed with the threshold of significance set at P < 0.05.
RESULTS
Participant Characteristics
Ten ES and eight control subjects completed the study protocol. The age (62.5 AE 2.8 and 58.5 AE 4.7 years, P ¼ 0.47) and sex distributions (30% and 25% female, respectively, P ¼ 0.80), preoperative body weight (BW) and body mass index (BMI) were similar between control and ES groups (86.4 AE 4.1 vs 84.3 AE 5.9 kg, P ¼ 0.78 and 28.8 AE 1.5 vs 28.9 AE 1.3 kg/m Table 1 , http://links.lww.com/SLA/A839. Tumor location was predominantly AEG I (70%) and the cohort comprised patients with either early tumors (Tis/T1, 60%) or an excellent response to neoadjuvant chemoradiation (cT3, 40%; ypN0 90%). Patients had undergone R0 resection with gastric conduit reconstruction and pyloroplasty (60% Ivor Lewis, 40% transhiatal esophagectomy) 2.4 AE 0.2 years before study assessment.
Postoperative Weight Outcomes
Significant body weight loss (BWL) occurred over the first 3 postoperative months (Fig. 3) , with percent BWL of 12.3% AE 3.1% observed at 3 months postoperatively (P < 0.05 vs baseline). After this BW remained stable albeit reduced from baseline, with 13.0% AE 4.0% and 11.6% AE 3.6 % BWL (both P < 0.05 vs baseline) observed at 1 and 2 years postoperatively.
Plasma Ghrelin
There was no significant difference in fasting (ES: 396.8 AE 77. 4 
Plasma GLP-1 and PYY
Fasting plasma total GLP-1 (ES: 60.9 AE 10.0, control: 45.3 AE 5.2 pM, P ¼ 0.33) and PYY levels (ES: 81.2 AE 9.9, control: 73.4 AE 10.1 pg/ml, P ¼ 0.65) were similar between ES and controls (Fig. 4) . A postprandial increase in GLP-1 and PYY was observed in both control (P ¼ 0.008 and 0.03) and ES (P ¼ 0.002 and 0.004) subjects on the placebo day. However, postprandial GLP-1 and PYY concentrations were approximately two-fold greater among ES subjects (GLP-1: 159.9 AE 22.6 pM; PYY: 283.9 AE 9.9 pg/mL) compared with controls (GLP-1: 74.6 AE 8. 2. Study design. This was a randomized, double-blind crossover study. Each participant attended on two occasions and received 0.9% saline or octreotide by subcutaneous injection in a computergenerated [RMcH] random order. Phlebotomy for gut hormones was performed immediately before and at 130 minutes after subcutaneous injection (50 minutes after meal initiation). The ad libitum meal was initiated at 80 minutes after subcutaneous injection. Additional phlebotomy for glucose took place at 75, 100, and 160 minutes after SC injection, and visual analog scales were applied before and at 60, 75, and 100 minutes after SC injection, and at 5, 10, 20, 40, and 60 minutes after completion of the ad libitum meal (timepoints not shown). (Fig. 4B) . The postprandial PYY response was similarly attenuated after administration of octreotide in both ES and controls ( Fig. 4C and D) .
Ad Libitum Calorie Intake
There was no difference in hunger or fullness at baseline on each study day for either group (ES: P ¼ 0.86, 0.63; control: P ¼ 0.88, 0.12) ( Supplementary Fig. 1 , http://links.lww.com/SLA/ A839). After placebo, there was a trend towards greater ad libitum calorie intake (Fig. 5 ) among controls as compared with ES (998.8 AE 253.3 vs 658.6 AE 78.9 kcal, P ¼ 0.08). For control subjects, there was no difference in ad libitum calorie intake after administration of octreotide versus placebo (1.1 AE 0.1 fold change, 1101.0 AE 305.3 vs 998.8 AE 253.3 kcal, P ¼ 0.30). However, octreotide was associated with an increase in ad libitum calorie intake for the ES group (1.5 AE 0.2 fold increase, 1106.0 AE 160.5 vs 658.6 AE 78.9 kcal, P ¼ 0.02). Despite increased ad libitum calorie intake, there was no difference in postprandial fullness or nausea after octreotide versus placebo (P ¼ 0.44, 0.16) (Supplementary Fig. 1 , http://links.lww.com/SLA/A839).
DISCUSSION
Changes in hunger and satiety are commonly observed after major upper gastrointestinal surgery; however, both are poorly understood and under-researched. In this study, we observed that patients after esophagectomy with gastric conduit reconstruction and pyloroplasty demonstrate an exaggerated postprandial GLP-1 and PYY response that is attenuated by subcutaneous octreotide with consequent increased ad libitum calorie intake. This provides an intriguing insight into a pathway that may be targeted in patients with recalcitrant symptoms impacting recovery of nutritional wellbeing and quality of life after esophagectomy.
The homeostatic regulation of appetite in the hypothalamic arcuate nucleus is modulated by afferent factors via appetite-FIGURE 3. Pre-and postoperative weight change among disease-free postesophagectomy subjects. Significant percentage body weight loss from preillness weight was observed from 3 months postoperatively (P < 0.05) and body weight remained significantly reduced compared with baseline at 3, 6, 12, and 24 months postoperatively (P < 0.05 for all timepoints). Mean AE SEM weight loss at 24 months postoperatively was 11.6% AE 3.6%. Mean AE SEM, ANOVA with posthoc Dunnett's multiple comparisons test. inhibiting proopiomelanocortin (POMC) and/or appetite-stimulating neuropeptide Y (NPY) and agouti-related peptide (AgRP) coexpressing neurons (Fig. 1) . 22, 25 The primary orexigenic hormone ghrelin increases NPY/AgRP activity resulting in increased appetite and food intake. 22, 25, 37 In the current study, fasting ghrelin levels were similar between controls and patients approximately 2 years postesophagectomy, consistent with previous reports suggesting postoperative recovery of ghrelin production in the long-term after surgery, 16, 18, 19 implicating other mediators as key to altered food intake and persistent body weight reduction in the longterm after esophagectomy.
The satiety gut hormones GLP-1 and PYY are secreted from the enteroendocrine L-cells of the small intestine in response to luminal nutrients and provide a meal termination signal, simultaneously increasing POMC and reducing NPY/AgRP. 22 GLP-1 may also act via the vagus nerve. However the current study in vagal-denervated esophagectomy patients suggests that intact vagal afferents are not required for the satiety-inducing effects of GLP-1. 37 The mechanism underlying exaggerated postprandial secretion of GLP-1 and PYY after esophagectomy is unclear, but may involve rapid delivery of nutrients into the small bowel, resulting in increased L-cell exposure to nutrients early after meal initiation. 31 Gastric emptying and small intestinal transit times inversely correlate with postprandial GLP-1 levels in patients post Roux-en-Y gastric bypass and VSG, 31, [38] [39] [40] and rapid gastric emptying has been reported in association with exaggerated GLP-1 secretion among postesophagectomy subjects. 31 A rapid and transient increase in postprandial plasma glucose concentrations was observed in the current ES cohort compared with controls, supporting the hypothesis that rapid transit into the small intestine initiates an exaggerated L-cell response postesophagectomy.
GLP-1 physiologically stimulates somatostatin release from pancreatic and gastric D-cells. Somatostatin, in turn, reduces L-cell secretion of GLP-1 and PYY in a negative feedback loop. [28] [29] [30] However the regulatory efficacy of endogenous somatostatin may be limited in conditions associated with exaggerated secretion of GLP-1 and PYY. 41 The somatostatin analog octreotide has an elimination half-life after SC injection of approximately 100 minutes and effectively inhibits enteroendocrine secretion of satiety gut hormones including GLP-1, as shown in the current study. 27 Here, attenuation of the exaggerated postprandial GLP-1 and PYY responses was associated with a significant increase in ad libitum calorie intake, suggesting that exaggerated satiety gut hormone responses may play a pathophysiologic role in the development of early satiety after esophagectomy.
Considering the nonspecific inhibitory effect of octreotide, 25 the resultant changes in calorie intake are unlikely to be exclusively due to blockade of GLP-1 and PYY responses, but may also involve down regulation of other postprandial satiety gut hormones, such as oxyntomodulin (OXM). 41 This notwithstanding, given that GLP-1, PYY, and OXM demonstrate additive inhibitory effects on food intake, 42, 43 the pleiotropic nature of the blockade achieved with octreotide may in fact be therapeutically advantageous for this cohort. Further studies investigating specific gut hormone inhibitors such as exendin-(9-39) may delineate the individual contributions of various gut hormones to early satiety after esophagectomy. Additionally, a greater understanding of the stimuli initiating exaggerated gut hormone responses after esophagectomy and the interaction with other postoperative phenomena such as malabsorption 44 may facilitate development of therapeutic, reconstructive, and dietary strategies that can effectively attenuate the long-term nutritional and quality of life implications associated with potentially curative resection for EC. In conclusion, this study identifies postprandial satiety gut hormone responses as a novel and viable therapeutic target for the modulation of early satiety to increase food intake after esophagectomy with gastric conduit. Although the prospective, randomized, crossover study design is very good, the number of patients and the individuals in the control group are, however, very small. I have three questions.
First, the surgical procedures were transthoracic and transhiatal esophagectomy. Does this have an effect on the nutritional function postoperatively?
Second, the control group comprises only eight individuals. Some of the results are not significantly different for the control group, but in the group of patients with esophagectomy, there are clear differences. How should this be interpreted?
Finally, measurement of reaction to octreotide was performed in a single event and it was shown that patients after esophagectomy could eat a greater amount of a standardized meal with octreotide rather than without octreotide. Does this lead to a significant increase in body weight? Is the injection of octreotide feasible as a long-term supplementation? What about tachyphylaxis of the octreotide effects?
Response From J.A. Elliott (Dublin, Ireland):
Thank you Professor Hoelscher for your questions, which I will address one by one.
Firstly, in terms of including patients who were posttranshiatal as compared with transthoracic resection, retrospective review of weight loss outcomes at our center showed no difference in percentage body weight loss among disease-free patients 2 years after transhiatal versus transthoracic resection. Rather than the surgical approach, it is likely that the nature of the reconstruction and postoperative nutrient transit are the key factors influencing the development of an exaggerated postprandial satiety gut hormone response. As such, we elected to include patients after both transthoracic and transhiatal resection in this study.
There were eight patients in our control group and 10 patients in our esophagectomy group. This study was powered based on the food intake data from le Roux et al, published in Annals of Surgery, 2007, with a similar design but looking at patients post Roux-en-Y gastric bypass surgery. We calculated that six patients would be required per group to detect a 50% AE 30% change in food intake. We were thus sufficiently powered in both groups to detect this large effect size, so any lack of an effect in the control group is quite relevant. I also want to highlight that the lack of an effect in the control group (who had normal postprandial gut hormone responses) in fact validates the previous data reported in 2007, wherein the control group comprising six patients with post laparoscopic gastric band placement also showed no change in food intake associated with normal postprandial gut hormone levels after administration of octreotide.
In response to your final question, this was a cross-sectional study. We wanted to initially determine whether this was a reasonable approach to increase food intake in this patient cohort before moving forward to examine weight gain. The next step will be to conduct a randomized control trial looking at the efficacy of octreotide for patients postesophagectomy, with the primary outcome measure being body weight change and the secondary outcome measures being changes in body composition and quality of life and gastrointestinal symptom scores.
In terms of tachyphylaxis, current short-acting somatostatin analogs have a life of approximately 100 minutes, and hence we can speculate that these agents may generate less tachyphylaxis than long-acting formulations. However, whether tachyphylaxis as regards to gut hormone suppression occurs with any of the somatostatin analogs remains to be determined.
D. Alderson (Birmingham, UK):
I have two simple questions. First, some patients complain of injection site pain with somatostatin. What measures did you take to ensure that the patients were not aware that they had actually received somatostatin because they experienced injection site discomfort? Second, the scientific rationale for your study is based on bariatric surgery but the oesophagectomized patients have been vagotomized. A transposed stomach has to empty and be subject to fluctuations in intra-thoracic pressure. I wonder how much of your effect is related to alterations in gastrointestinal motility rather than being directly affected in the way that you would perhaps imply.
Thank you for your questions Professor Alderson. Firstly, the patients were blinded and had not received octreotide before. Thus, they did not associate painful injections with octreotide. Secondly, the investigators were blinded as to what the patients were receiving. The randomization and blinding was performed by an external pharmacist involved in the study. It is true that octreotide can cause some injection site discomfort but so can 0.9% saline used as a placebo.
As to whether the effect of octreotide is mediated by its effect on gastrointestinal motility, as opposed to gut hormone suppression, I think that it is likely that these two phenomena are not mutually exclusive. It is possible that the effect of octreotide on the postprandial gut hormone response may be mediated both by its direct effect on the L-cell, which is well established, and perhaps partly mediated by its effect on gastrointestinal motility. However, I don't think this represents a limitation of somatostatin as therapeutic, and may actually increase its utility in this context.
G. Zaninotto (London, UK):
Just a short question: Did you observe any effect of octreotide on other symptoms such as early dumping or steatorrhea?
We didn't measure dumping symptoms on the study days. We did ask the patients to complete a Sigstad score on recruitment into the study and although we were probably underpowered for this outcome, it did appear that patients with more profound symptoms as measured by Sigstad score demonstrated a greater increase in food intake after the administration of octreotide. I think that would suggest that this exaggerated postprandial gut hormone response may be a marker of a broader alteration in postoperative gastrointestinal physiology in these patients. Steatorrhea can occur after administration of octreotide and is seen in approximately 10% of patients in our studies. It tends to be a transient occurrence after single dose octreotide administration; however, the natural history of this phenomenon in long-term treatment is not well documented.
